Cognetivity Neurosciences (CGN.C) announced today that its Integrated Cognitive Assessment (ICA) will become an integral part of a new and highly innovative clinic in the UK’s Nation Health Service (NHS) dedicated to driving improvements in early-stage dementia diagnosis.



“We’re thrilled to see the ICA deployed as part of this ground-breaking new clinic at one of the UK’s premier mental health trusts. Early-stage diagnosis, facilitated by remote cognitive assessment and monitoring – this is the bright future of dementia medicine, without a doubt, and we’re delighted to be a part of it,” said Dr. Sina Habibi, Cognetivity’s CEO.

Cognetivity’s ICA is set to be deployed within a new, remote Brain Health Clinic at South London and Maudsley NHS Foundation Trust (SLaM). SLaM is responsible for providing the widest range of NHS mental health services in the UK. The organization serves a local population of nearly two million, offering more than 230 services including inpatient wards, outpatient and community services. Moreover, SLaM provides inpatient care to more than 5,000 patients every year.


With this in mind, Cognetivity’s ICA has been recognized by one of the most renowned NHS foundation trusts in the UK. Furthermore, the proposed clinic is expected to become the first of its kind in the world, offering in-depth subtyping of patients with mild cognitive impairment (MCI), followed by periodic, remote assessment of those who are likely to progress to Alzheimer’s dementia. Ultimately, this clinic is intended to enhance the early diagnosis of patients living with Alzheimer’s disease and provide timely access to treatment.


With that being said, there is no better partner for SLaM than Cognetivity. In numerous clinical trials and peer-reviewed publications, the Company’s ICA has demonstrated superior sensitivity to early-stage cognitive impairment. Additionally, as a computerized, iPad-based test, Cognetivity’s ICA is able to support the clinic’s commitment to remote medical assessment.

“This clinic is a really exciting prospect for dementia diagnosis and care…It’s fantastic to have the ICA involved, as a highly innovative tool, fit for a highly innovative project, that brings enormous potential to improve patient outcomes,” said senior NHS geriatric psychiatrist Professor Dag Aarsland, who has overseen the clinic’s creation.

Having only just recently launched in the Middle East, Cognetivity’s ICA is making quite a name for itself, both locally and globally. With plans to integrate ICA into SLaM’s upcoming remote clinic, The London-based company now has an even greater foothold in the UK’s mental health sector. Furthermore, technologies like Cognetivity’s ICA have become increasingly important in the wake of new therapies for Alzheimer’s including aducanumab, a drug recently approved by the FDA. For more information related to Cognetivity’s ICA and financial position, check out this article.

Cognetivity’s share price opened at $1.01, down from a previous close of $1.02. The Company’s shares are down -5.88% and are currently trading at $0.96 as of 2:18PM ET.

Written By:

Kieran Robertson

Kieran Robertson is an experienced writer with a passion for technology, esports, and video games. He graduated from the University of Western Ontario with a Major in English Language and Literature. After graduating, Kieran worked as a freelance writer, managing his own blog and volunteering for La Maza Magazine, a magazine startup focused on collaborating with photographers, writers, models, and designers.

More By This Author
Health Science
Medical Devices
Alzheimer's detection
Cognetivity Neurosciences
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x